Poor
Not Aligned
Patient Risk:
Low
Summary
Overall alignment is poor. Many claims are not verifiable from the provided label excerpts (notably indications/usage), and several hypersensitivity symptom and allergy-risk-reduction instructions are not supported by the included Warnings/Counseling text. Additional claims include unsupported generalizations (e.g., 'rare', 'most common') and an unsupported mechanism-to-outcome statement ('slow down disease progression').
Category Scores
Accurate Statements
Cosentyx is a monoclonal antibody that works by blocking the action of interleukin-17A (IL-17A).
12.1 Mechanism of Action: binds IL-17A and inhibits its interaction with the IL-17 receptor.
Cosentyx can cause nasopharyngitis.
6.1/Table 2: Nasopharyngitis is listed; also 5.1 infection rates include nasopharyngitis.
Cosentyx can cause headache.
6.1/PsA adverse events: headache listed among adverse events at ≥2% in COSENTYX vs placebo (per provided excerpt).
Patients should report symptoms to their healthcare provider promptly when taking Cosentyx.
17: advises seeking immediate medical attention for serious hypersensitivity symptoms; 5.1: instructs patients to seek medical advice if signs/symptoms suggestive of infection occur.
Unsupported Statements
Cosentyx (secukinumab) is a biologic medication used to treat autoimmune diseases such as psoriasis, psoriatic arthritis, and ankylosing spondylitis.
Indications and Usage section (Section 1) was not available/empty in the provided evidence, so approved uses cannot be verified.
By inhibiting IL-17A, Cosentyx helps to reduce inflammation and slow down disease progression.
Label text supports inhibition of proinflammatory cytokines/chemokines, but 'slow down disease progression' is not supported by the provided excerpts.
Cosentyx can cause injection site reactions (e.g., redness, swelling, pain).
No provided label excerpt supports injection site reactions or the example symptoms.
Cosentyx can cause upper respiratory tract infections (e.g., bronchitis, pneumonia).
Provided label supports upper respiratory tract infection as an adverse reaction/infection category, but bronchitis/pneumonia are not specifically supported by the provided excerpts.
Cosentyx can cause fatigue.
No provided label excerpt mentions fatigue as an adverse reaction.
Cosentyx can cause muscle pain.
No provided label excerpt mentions muscle pain as an adverse reaction.
Allergic reactions to Cosentyx are rare but can be severe.
Severe hypersensitivity is supported, but 'rare' is not supported by the provided excerpts.
In clinical trials, the most common allergic reactions reported for Cosentyx included hypersensitivity reactions (e.g., anaphylaxis, angioedema).
Provided excerpts do not support these as 'most common' clinical-trial allergic reactions.
In clinical trials, the most common allergic reactions reported for Cosentyx included urticaria (hives).
Urticaria is listed with rates, but the provided excerpts do not support it as 'most common' among allergic reactions.
In clinical trials, the most common allergic reactions reported for Cosentyx included pruritus (itching).
No provided label excerpt supports pruritus.
In clinical trials, the most common allergic reactions reported for Cosentyx included rash.
No provided label excerpt supports rash as a clinical-trial allergic reaction in the cited evidence.
Symptoms of an allergic reaction to Cosentyx can include difficulty breathing or swallowing.
Hypersensitivity symptom details of this type are not supported by provided 5.2/17 excerpts.
Symptoms of an allergic reaction to Cosentyx can include swelling of the face, lips, tongue, or throat.
Provided 5.2 excerpt references anaphylaxis/angioedema but does not provide the specific symptom-location detail as stated.
Symptoms of an allergic reaction to Cosentyx can include abdominal pain or diarrhea.
Not supported by the provided hypersensitivity/counseling excerpts.
Symptoms of an allergic reaction to Cosentyx can include rapid heartbeat or palpitations.
Not supported by the provided hypersensitivity/counseling excerpts.
To minimize the risk of allergic reactions, patients should monitor their body's response to Cosentyx closely.
The provided label excerpts instruct immediate medical attention for serious hypersensitivity symptoms, but do not include this specific phrasing.
Patients should attend regular follow-up appointments to discuss the treatment plan and concerns related to Cosentyx.
No follow-up appointment instruction was present in the provided excerpts.
Patients should inform their healthcare provider about any pre-existing allergies or sensitivities before taking Cosentyx.
No general instruction for disclosing pre-existing allergies/sensitivities is present in the provided excerpts (aside from latex-specific counseling).
In the event of an allergic reaction to Cosentyx, patients should call their healthcare provider or emergency services immediately.
Label excerpts support immediate medical attention/discontinuation, but do not specifically mention calling healthcare provider or emergency services.
In the event of an allergic reaction to Cosentyx, epinephrine should be administered if prescribed.
No epinephrine instruction appears in the provided 5.2 or 17 excerpts.
In the event of an allergic reaction to Cosentyx, patients should take antihistamines or corticosteroids as directed by their healthcare provider.
No antihistamine/corticosteroid instruction appears in the provided 5.2 or 17 excerpts.
In the event of an allergic reaction to Cosentyx, patients should seek medical attention at a hospital or urgent care center.
Provided label supports immediate medical attention but does not specify hospital/urgent care.
To minimize the risk of an allergic reaction, patients should read the medication label carefully before administration of Cosentyx.
The label supports advising patients to read FDA-approved patient labeling, but the provided excerpts do not explicitly link this instruction to minimizing allergic-reaction risk.
To minimize the risk of an allergic reaction, patients should wash their hands before and after handling Cosentyx.
No hand-washing instruction is present in the provided excerpts.
To minimize the risk of an allergic reaction, patients should use a new needle and syringe for each injection of Cosentyx.
Label excerpt addresses not reusing syringe/needle and disposal, but the specific 'new needle and syringe for each injection' instruction is not explicitly supported in the provided text.
To minimize the risk of an allergic reaction, patients should avoid touching their eyes or mouth after handling Cosentyx.
No instruction about avoiding touching eyes or mouth after handling is present in the provided excerpts.
Contradictions
Important Omissions
Approved indication details (Section 1) and dosing/administration specifics are not present in the provided label evidence, preventing verification of multiple therapeutic and administration-related aspects.
Importance:
High
Boxed warnings, contraindications, and key risk management details could not be assessed because those sections were not provided in the evidence set.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
Most problematic issues are lack of label support/verification rather than direct contradictions. However, unsupported detailed hypersensitivity symptom content and unsupported procedural advice (e.g., epinephrine/antihistamines/corticosteroids, specific handling steps) could mislead patients if relied upon.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Not Aligned
Primary Issue
Multiple claims are not verifiable or unsupported by the provided label excerpts, especially indications/usage and hypersensitivity symptom/procedural guidance.
Suggested Improvement
Limit statements to mechanisms and adverse reactions explicitly supported by the provided label text; remove 'rare'/'most common'/symptom-detail claims not contained in 5.2 or 17; avoid adding handling or emergency-treatment instructions (epinephrine/antihistamines/corticosteroids, call provider/emergency services, hospital/urgent care) unless explicitly present in the supplied labeling.